1 281

Cited 40 times in

Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia

 J. W. Hong  ;  W. Nam  ;  I.-H. Cha  ;  S.-W. Chung  ;  H. S. Choi  ;  K. M. Kim  ;  K. J. Kim  ;  Y. Rhee  ;  S.-K. Lim 
 OSTEOPOROSIS INTERNATIONAL, Vol.21(5) : 847-853, 2010 
Journal Title
Issue Date
Administration, Oral ; Aged ; Aged, 80 and over ; Bone Density Conservation Agents/adverse effects* ; Bone Density Conservation Agents/therapeutic use ; Diphosphonates/adverse effects* ; Diphosphonates/therapeutic use ; Drug Administration Schedule ; Female ; Humans ; Jaw Diseases/chemically induced* ; Jaw Diseases/diagnostic imaging ; Jaw Diseases/therapy ; Male ; Middle Aged ; Osteonecrosis/chemically induced* ; Osteonecrosis/diagnostic imaging ; Osteonecrosis/therapy ; Osteoporosis/drug therapy ; Radiography, Panoramic ; Retrospective Studies ; Treatment Outcome
Bisphosphonate ; Jaw ; Osteonecrosis ; Osteomyelitis ; Osteoporosis
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect of bisphosphonate therapy. The incidence of BRONJ is known to be low among patients treated with oral bisphosphonates. We investigated the prevalence, demographics, clinical manifestations, and treatment outcome of 24 patients with oral BRONJ in Asian populations. INTRODUCTION: The long-term safety of oral bisphosphonates is clinically important considering the rare but potentially serious complications such as bisphosphonate-related osteonecrosis of the jaw (BRONJ) versus the effect of reducing and preventing osteoporotic fracture. The incidence of BRONJ is known to be low among patients treated with oral bisphosphonates around the world. However, the prevalence in those taking oral bisphosphonates for osteoporosis in Asian populations is unknown. Moreover, a recent article, showing that the majority of reported patients who received alendronate were Asian American, raised concern about the prevalence of oral BRONJ in Asian populations. The objective of this study was to investigate the estimated prevalence, clinical characteristics, and treatment outcome of oral BRONJ in Asian populations. METHODS: From October 2005 to December 2008, a retrospective review of medical charts identified 24 patients receiving oral bisphosphonates diagnosed as BRONJ at the Department of Oral and Maxillofacial Surgery, Yonsei University Dental Hospital, Seoul, South Korea. RESULTS: The estimated prevalence of oral BRONJ was 0.05-0.07%. The average oral bisphosphonate treatment duration was 43.1 months (range, 5-120 months). Treatment with oral antibiotics and/or surgery including sequestrectomy or alveolectomy showed relatively favorable results. CONCLUSIONS: The prevalence of oral BRONJ in Korea is similar to that reported previously in Western populations. We suggest that recognition of BRONJ and appropriate management pre- and post-dental surgery might reduce the frequency of BRONJ among patients receiving oral bisphosphonates.
Full Text
Appears in Collections:
2. College of Dentistry (치과대학) > Dept. of Oral and Maxillofacial Surgery (구강악안면외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Min(김경민)
Kim, Kwang Joon(김광준) ORCID logo https://orcid.org/0000-0002-5554-8255
Nam, Woong(남웅) ORCID logo https://orcid.org/0000-0003-0146-3624
Rhee, Yumie(이유미) ORCID logo https://orcid.org/0000-0003-4227-5638
Lim, Sung Kil(임승길)
Chung, Seung Won(정승원)
Cha, In Ho(차인호) ORCID logo https://orcid.org/0000-0001-8259-2190
Choi, Han Seok(최한석)
Hong, Jae Won(홍재원)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.